Evidence map›Paper›PMID 38907159›Full record

Trial reportNature medicine2024

Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAF

Georgina V Long, Matteo S Carlino, George Au-Yeung, Andrew J Spillane, Kerwin F Shannon, David E Gyorki, Edward Hsiao, Rony Kapoor, Jake R Thompson, Iris Batula and 8 more

Abstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Cancer-related fatigue during treatment with neoadjuvant and/or adjuvant immune checkpoint inhibitors: a systematic review and meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Pooled it
  2. Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: a joint SITC and INMC effort.Annals of oncology : official journal of the European Society for Medical Oncology · 2026
    Guideline
  3. Trial
  4. Review
  5. Article
  6. Review
  7. [European journal of nuclear medicine and molecular imaging · 2026
    Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. [Neoadjuvant treatment of melanoma].Dermatologie (Heidelberg, Germany) · 2025
    Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Georgina V LongMelanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia. georgina.long@sydney.edu.au.ORCID http://orcid.org/0000-0001-8894-3545
Matteo S CarlinoMelanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
George Au-YeungPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Andrew J SpillaneMelanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.ORCID http://orcid.org/0000-0002-9520-0181
Kerwin F ShannonMelanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.ORCID http://orcid.org/0000-0001-8538-3132
David E GyorkiPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Edward HsiaoRoyal North Shore Hospital, Sydney, New South Wales, Australia.ORCID http://orcid.org/0000-0003-4882-0297
Rony KapoorMater Hospital, Sydney, New South Wales, Australia.
Jake R ThompsonMelanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
Iris BatulaMelanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
Julie HowleWestmead Hospital, Westmead, New South Wales, Australia.
Sydney Ch'ngMelanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.ORCID http://orcid.org/0000-0002-4011-1253
Maria GonzalezMelanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
Robyn P M SawMelanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.ORCID http://orcid.org/0000-0002-3354-806X
Thomas E PenningtonMelanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
Serigne N LoMelanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.ORCID http://orcid.org/0000-0001-5092-5544
Richard A ScolyerMelanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.ORCID http://orcid.org/0000-0002-8991-0013
Alexander M MenziesMelanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint inhibitors and BRAF-targeted therapy each improve survival in melanoma. Immune changes early during targeted therapy suggest the mechanisms of each drug class could work synergistically. In the non-comparative, randomized, phase 2 NeoTrio trial, we investigated whether targeted therapy could boost the proportion of patients achieving long-term recurrence-free survival with neoadjuvant immunotherapy in resectable stage III BRAF

Indexed as

Antibodies, Monoclonal, HumanizedImidazolesMelanomaOximesProto-Oncogene Proteins B-rafPyridonesPyrimidinonesAdultAgedAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansImmunotherapyMaleMiddle AgedMutationAntibodies, Monoclonal, HumanizedBRAF protein, humandabrafenibImidazolesOximespembrolizumabProto-Oncogene Proteins B-rafPyridonesPyrimidinonestrametinib

Identifiers

PMID38907159
PMCPMC11405264

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.